Integration of PEGylation and refolding for renaturation of recombinant proteins from insoluble aggregates produced in bacteria-Application to a single-chain Fv fragment

Journal of Bioscience and Bioengineering

Volumn 109, Issue 5, 2010, Pages 447-452

  Kumagai, Izumi ^a   Asano, Ryutaro ^a   Nakanishi, Takeshi ^a   Hashikami, Kentaro ^a   Tanaka, Sho ^a   Badran, Adel ^a   Sanada, Hideaki ^a   Umetsu, Mitsuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

In vitro refolding; PEGylation; Recombinant antibody; scFv; Therapeutic protein

Indexed keywords

IN-VITRO; PEGYLATION; RECOMBINANT ANTIBODY; REFOLDING; THERAPEUTIC PROTEIN;

AGGLOMERATION; ESCHERICHIA COLI; MONOCLONAL ANTIBODIES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES;

PROTEINS;

CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONJUGATION; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; GENE INSERTION; NONHUMAN; PEGYLATION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN RENATURATION; PROTEIN SYNTHESIS;

DRUG CARRIERS; ESCHERICHIA COLI; POLYETHYLENE GLYCOLS; PROTEIN DENATURATION; PROTEIN ENGINEERING; PROTEIN FOLDING; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; SOLUBILITY;

ESCHERICHIA COLI;

EID: 77949882945     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2009.10.016     Document Type: Article

References (33)

1. Anand N.N., Mandal S., MacKenzie C.R., Sadowska J., Sigurskjold B., Young N.M., Bundle D.R., and Narang S.A. Bacterial expression and secretion of various single-chain Fv genes encoding proteins specific for a Salmonella serotype B O-antigen. J. Biol. Chem. 266 (1991) 21874-21879
2. Venturi M., Seifert C., and Hunte C. High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J. Mol. Biol. 315 (2002) 1-8
3. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
4. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54 (2002) 531-545
5. Weir A.N., Nesbitt A., Chapman A.P., Popplewell A.G., Antoniw P., and Lawson A.D. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 30 (2002) 512-516
6. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12 (2001) 195-202
7. Greenwald R.B., Choe Y.H., McGuire J., and Conover C.D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55 (2003) 217-250
8. Kubetzko S., Sarkar C.A., and Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68 (2005) 1439-1454
9. Glockshuber R., Schmidt T., and Pluckthun A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry 31 (1992) 1270-1279
10. Field H., Yarranton G.T., and Rees A.R. Expression of mouse immunoglobulin light and heavy chain variable regions in Escherichia coli and reconstitution of antigen-binding activity. Protein Eng 3 (1990) 641-647
11. Pluckthun A. Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding. Immunol. Rev. 130 (1992) 151-188
12. Malby R.L., Caldwell J.B., Gruen L.C., Harley V.R., Ivancic N., Kortt A.A., Lilley G.G., Power B.E., Webster R.G., Colman P.M., and Hudson P.J. Recombinant antineuraminidase single chain antibody: expression, characterization, and crystallization in complex with antigen. Proteins 16 (1993) 57-63
13. Tsumoto K., Shinoki K., Kondo H., Uchikawa M., Juji T., and Kumagai I. Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent-application to a human single-chain Fv fragment. J. Immunol. Methods 219 (1998) 119-129
14. Umetsu M., Tsumoto K., Hara M., Ashish K., Goda S., Adschiri T., and Kumagai I. How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system. Spectroscopic evidence for highly efficient refolding of a single-chain Fv fragment. J. Biol. Chem. 278 (2003) 8979-8987
15. Asano R., Sone Y., Makabe K., Tsumoto K., Hayashi H., Katayose Y., Unno M., Kudo T., and Kumagai I. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin. Cancer Res. 12 (2006) 4036-4042
16. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23 (2003) 3S-8S
17. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
18. Hinds K.D., and Kim S.W. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54 (2002) 505-530
19. George A.J., Titus J.A., Jost C.R., Kurucz I., Perez P., Andrew S.M., Nicholls P.J., Huston J.S., and Segal D.M. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J. Immunol. 152 (1994) 1802-1811
20. Verma R., Boleti E., and George A.J. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods 216 (1998) 165-181
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
22. Asano R., Watanabe Y., Kawaguchi H., Fukazawa H., Nakanishi T., Umetsu M., Hayashi H., Katayose Y., Unno M., Kudo T., and Kumagai I. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J. Biol. Chem. 282 (2007) 27659-27665
23. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., and Oppermann H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 5879-5883
24. Gruber M., Schodin B.A., Wilson E.R., and Kranz D.M. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152 (1994) 5368-5374
25. Holliger P., Prospero T., and Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6444-6448
26. Kipriyanov S.M., Moldenhauer G., Schuhmacher J., Cochlovius B., Von der Lieth C.W., Matys E.R., and Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293 (1999) 41-56
27. Hu S., Shively L., Raubitschek A., Sherman M., Williams L.E., Wong J.Y., Shively J.E., and Wu A.M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56 (1996) 3055-3061
28. Yang K., Basu A., Wang M., Chintala R., Hsieh M.C., Liu S., Hua J., Zhang Z., Zhou J., Li M., et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 16 (2003) 761-770
29. Ramm K., Gehrig P., and Pluckthun A. Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J. Mol. Biol. 290 (1999) 535-546
30. Buchner J., and Rudolph R. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology. (N. Y). 9 (1991) 157-162
31. Qiao Z.S., Guo Z.Y., and Feng Y.M. Putative disulfide-forming pathway of porcine insulin precursor during its refolding in vitro. Biochemistry 40 (2001) 2662-2668
32. Ahn J.H., Lee Y.P., and Rhee J.S. Investigation of refolding condition for Pseudomonas fluorescens lipase by response surface methodology. J. Biotechnol. 54 (1997) 151-160
33. Hayashi H., Asano R., Tsumoto K., Katayose Y., Suzuki M., Unno M., Kodama H., Takemura S., Yoshida H., Makabe K., et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol. Immunother. 53 (2004) 497-509